

Fig. S5

Supplementary Fig S5. MCT-1/IL-6/IL-6R signaling promotes breast cancer stemness. IL-6 (50 ng/ml) was used to treat MDA-MB-231 cells for 14-17 days. Mammosphere formation **(A)**, MCT-1 **(B)**, CD44 **(C)**, CD133 **(D)**, ALDH-1 **(E)**, Oct-4 **(F)**, Sox-2 **(G)** and Nanog **(H)** mRNA levels were analyzed. IL-6R was evaluated in day 14 mammospheroids with different MCT-1 levels **(I)**. Upon tocilizumab (200 mg/ml) treatment for 14 days, the MDA-MB-231 mammospheroids (≧50 μm) **(J)**, IL-6R **(K)**, IL-6 **(L)**, CD44 **(M)**, ALDH-1 **(N)**, EpCAMP **(O)** and Oct4 **(P)** mRNA levels were analyzed. CD44(+)/CD24(-) subpopulations in day 21 mammospheres were measured by flow cytometry using CD44-FITC and CD24-PE staining **(Q)**. The results are expressed as the mean ± SD (n=3). One-way ANOVA with a post hoc two-tailed t-test was used to calculate the statistical significance of pairwise comparisons. (*p<0.05; **p<0.01; *** p<0.001)